BLACK DIAMOND THERAPEUTICS, INC. Shareholders' Equity
BLACK DIAMOND THERAPEUTICS, INC. (BDTX) had Shareholders' Equity of $96.09 million as of 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Balance Sheet › Equity › Equity, Attributable to Parent
us-gaap:StockholdersEquity · last filed 2026-08-05
- 2026-06-30: Stockholders' Equity Attributable to Parent $96.09M.
- 2026-03-31: Stockholders' Equity Attributable to Parent $104.30M.
- 2025-12-31: Stockholders' Equity Attributable to Parent $112.21M.
- 2025-09-30: Stockholders' Equity Attributable to Parent $126.15M.
| Period end | Stockholders' Equity Attributable to Parent | Stockholders' Equity Attributable to Parent as first filed |
|---|---|---|
| 2026-06-30 | $96.09M 10-Q · filed 2026-08-05 | |
| 2026-03-31 | $104.30M 10-Q · filed 2026-08-05 | |
| 2025-12-31 | $112.21M 10-Q · filed 2026-08-05 | |
| 2025-09-30 | $126.15M 10-Q · filed 2025-11-06 | |
| 2025-06-30 | $132.61M 10-Q · filed 2026-08-05 | |
| 2025-03-31 | $141.52M 10-Q · filed 2026-08-05 | |
| 2024-12-31 | $83.28M 10-Q · filed 2026-08-05 | |
| 2024-09-30 | $97.43M 10-Q · filed 2025-11-06 | |
| 2024-06-30 | $110.52M 10-Q · filed 2025-11-06 | $111.02M 10-Q · filed 2024-08-06 |
| 2024-03-31 | $104.31M 10-Q · filed 2025-11-06 | |
| 2023-12-31 | $116.74M 10-K · filed 2026-03-16 | |
| 2023-09-30 | $134.32M 10-Q · filed 2024-11-05 | |
| 2023-06-30 | $82.20M 10-Q · filed 2024-11-05 | |
| 2023-03-31 | $98.19M 10-Q · filed 2024-11-05 | |
| 2022-12-31 | $115.69M 10-K · filed 2025-03-06 | |
| 2022-09-30 | $133.23M 10-Q · filed 2023-11-06 | |
| 2022-06-30 | $152.37M 10-Q · filed 2023-11-06 | |
| 2022-03-31 | $172.56M 10-Q · filed 2023-11-06 | |
| 2021-12-31 | $195.90M 10-K · filed 2024-03-12 | |
| 2021-09-30 | $218.95M 10-Q · filed 2022-11-08 | |
| 2021-06-30 | $251.02M 10-Q · filed 2022-11-08 | |
| 2021-03-31 | $280.75M 10-Q · filed 2022-11-08 | |
| 2020-12-31 | $307.76M 10-K · filed 2023-03-09 | |
| 2020-09-30 | $327.35M 10-Q · filed 2021-11-08 | |
| 2020-06-30 | $343.13M 10-Q · filed 2021-11-08 | |
| 2020-03-31 | $355.26M 10-Q · filed 2021-11-08 | |
| 2019-12-31 | -$47.16M 10-K · filed 2022-03-17 | |
| 2019-09-30 | -$39.79M 10-Q · filed 2020-11-10 | |
| 2019-06-30 | -$31.37M 10-Q · filed 2020-11-10 | |
| 2019-03-31 | -$19.28M 10-Q · filed 2020-11-10 | |
| 2018-12-31 | -$15.54M 10-K · filed 2021-03-25 | |
| 2017-12-31 | -$6.67M 10-K · filed 2020-03-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cardiff Oncology, Inc. (CRDF) | United States | $0.101B | -2.22 |
| LENZ Therapeutics, Inc. (LENZ) | United States | $0.117B | -1.41 |
| COGNITION THERAPEUTICS INC (CGTX) | United States | $0.090B | -6.52 |
| enGene Therapeutics Inc. (ENGN) | $0.129B | -0.92 | |
| Pelthos Therapeutics Inc. (PTHS) | United States | $0.086B | -1.20 |
| Atara Biotherapeutics, Inc. (ATRA) | United States | $0.086B | -6.48 |
| Neumora Therapeutics, Inc. (NMRA) | United States | $0.132B | -1.48 |
| Armata Pharmaceuticals, Inc. (ARMP) | United States | $0.132B | |
| Caribou Biosciences, Inc. (CRBU) | United States | $0.134B | -1.79 |
| Vaxart, Inc. (VXRT) | United States | $0.080B | 3.84 |